Analysis Quality & compliance

MHRA closes one IDAP authorisation as the pilot stays shut to new applicants

A small update to the UK's Innovative Devices Access Pathway page marks one authorisation closed. For quality teams, the lesson is about lifecycle tracking, not headlines.

VigiEye editorial · Fri 20 Nov 2026

What happened

On 19 November 2026 the MHRA revised its guidance page for the Innovative Devices Access Pathway (IDAP). The update shows that authorisation IDAP/DEU/009/2024/0001, described as an Unmet Clinical Need Authorisation, is now closed. The page also confirms that the IDAP pilot remains closed to new applicants.

The records say nothing beyond that. They do not name the device or the sponsor, and they give no reason for the closure. They do not say whether patients or users were transitioned to another route, or whether a successor scheme is planned. Anyone drawing conclusions about why the authorisation closed would be speculating.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →